<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>25C. GRAFT vs. HOST Disease</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-25b-transplantation-immunology-details.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 100%;"></div> <!-- (39/39)*100 -->
                        </div>
                       <span class="progress-text">Lecture 39 of 39</span> 
                    </div>
                    <a href="#" class="nav-button disabled"> <!-- Last chunk -->
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">GRAFT vs. HOST DISEASE.</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                <!-- START: section-learning-objectives -->
                <section id="section-learning-objectives" class="content-section" aria-labelledby="section-heading-learning-objectives">
                    <h2 id="section-heading-learning-objectives" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Learning Objectives:</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Be able to define the GVHD.</li>
                            <li>Be able to classify the organs most affected.</li>
                            <li>Be able to describe manifestations of GVHD in the affected organs.</li>
                            <li>Describe the mechanism of GVHD leading to tissue damage.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-learning-objectives -->

                <!-- START: section-introduction-gvhd -->
                <section id="section-introduction-gvhd" class="content-section" aria-labelledby="section-heading-introduction-gvhd">
                    <h2 id="section-heading-introduction-gvhd" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Introduction to Graft vs. Host Disease.</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Graft vs. Host disease is a syndrome that occurs when immune cells from a donor attack the host's normal cells.</li>
                            <li>GVHD is one of the major causes of morbidity and mortality associated with an allogenic stem cell transplant.</li>
                            <li>GVHD occurs in 30 to 50% of HLA-matched sibling transplants and 60 to 90% of mismatched.</li>
                            <li>Unfortunately at this time, we can not separate GVHD from the beneficial graft vs. leukemia effect.</li>
                            <li>GVHD is divided into acute and chronic depending on whether the initial symptoms developed before 100 days following Bone Marrow Transplant (BMT)</li>
                            <li>The organ systems primarily affected by acute GVHD are the skin, liver, and GI tract.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-introduction-gvhd -->

                <!-- START: section-manifestations-gvhd -->
                <section id="section-manifestations-gvhd" class="content-section" aria-labelledby="section-heading-manifestations-gvhd">
                    <h2 id="section-heading-manifestations-gvhd" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Manifestations of Graft vs. Host Disease.</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>The liver manifestations are primarily increases in the bilirubin but can also involve transaminitis</li>
                            <li>The GI manifestations are diarrhea, nausea, and vomiting.</li>
                            <li>The severity of acute GVHD is staged on a I to IV system.</li>
                        </ul>
                        <div class="table-container">
                            <table class="content-table">
                                <caption>Stage of Graft-Versus-Host-Disease by Organ System</caption>
                                <thead>
                                    <tr>
                                        <th>Organ</th>
                                        <th>Grade</th>
                                        <th>Description</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td rowspan="4">Skin</td>
                                        <td>+1</td>
                                        <td>Maculopapular rash over 25 percent of body area</td>
                                    </tr>
                                    <tr>
                                        <td>+2</td>
                                        <td>Maculopapular rash over 25 to 50 percent of body area</td>
                                    </tr>
                                    <tr>
                                        <td>+3</td>
                                        <td>Generalized erythroderma</td>
                                    </tr>
                                    <tr>
                                        <td>+4</td>
                                        <td>Generalized erythroderma with bullous formation and often with desquamation</td>
                                    </tr>
                                    <tr>
                                        <td rowspan="4">Liver</td>
                                        <td>+1</td>
                                        <td>Bilirubin 2.0 to 3.0 mg/dL; SGOT 150 to 750 IU/L</td> <!-- Corrected II to IU/L -->
                                    </tr>
                                    <tr>
                                        <td>+2</td>
                                        <td>Bilirubin 3.1 to 6.0 mg/dL</td>
                                    </tr>
                                    <tr>
                                        <td>+3</td>
                                        <td>Bilirubin 6.1 to 15.0 mg/dL</td>
                                    </tr>
                                    <tr>
                                        <td>+4</td>
                                        <td>Bilirubin >15.0 mg/dL</td> <!-- MMD had 15.0, typically >15.0 -->
                                    </tr>
                                    <tr>
                                        <td rowspan="4">Gut</td>
                                        <td>+1</td>
                                        <td>Diarrhea >30 mL/kg or >500 mL/day</td> <!-- Corrected x to > -->
                                    </tr>
                                    <tr>
                                        <td>+2</td>
                                        <td>Diarrhea >60 mL/kg or >1000 mL/day</td> <!-- Corrected 360 to >60, x to > -->
                                    </tr>
                                    <tr>
                                        <td>+3</td>
                                        <td>Diarrhea >90 mL/kg or >1500 mL/day</td> <!-- Corrected 990 to >90, x to > -->
                                    </tr>
                                    <tr>
                                        <td>+4</td>
                                        <td>Diarrhea >90 mL/kg or >2000 mL/day; or severe abdominal pain with or without ileus</td> <!-- Corrected 990 to >90, x to > -->
                                    </tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>
                <!-- END: section-manifestations-gvhd -->

                <!-- START: section-mechanism-acute-gvhd -->
                <section id="section-mechanism-acute-gvhd" class="content-section" aria-labelledby="section-heading-mechanism-acute-gvhd">
                    <h2 id="section-heading-mechanism-acute-gvhd" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Proposed mechanism for acute GVHD.</span>
                    </h2>
                    <div class="content-card">
                        <p>There appear to be 3 phases to the development of acute GVHD.</p>
                        <ol>
                            <li>Damage to host tissues.</li>
                            <li>Activation and proliferation of donor lymphocytes.</li>
                            <li>Attack on the host cells.</li>
                        </ol>
                        <figure>
                            <img src="../assets/images/2025_06_15_2bf39b8f0cf607742d85g-09-1.jpg" alt="Diagram illustrating the three phases of acute GVHD: 1. Tissue damage from conditioning regimen releases inflammatory cytokines. 2. Donor T-cells are activated by host APCs presenting alloantigens. 3. Activated donor T-cells attack host target tissues (skin, liver, gut)." class="content-image">
                        </figure>
                    </div>
                </section>
                <!-- END: section-mechanism-acute-gvhd -->

                <!-- START: section-phase1-damage-host -->
                <section id="section-phase1-damage-host" class="content-section" aria-labelledby="section-heading-phase1-damage-host">
                    <h2 id="section-heading-phase1-damage-host" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">I. Damage to the Host.</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>The damage primarily comes from the conditioning regimen.</li>
                            <li>The damage to the host leads to the release of inflammatory cytokines such as TNF-alpha and IL-1.</li>
                            <li>In the gut, microbial products such as lipopolysaccharide can enter the circulation.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-phase1-damage-host -->

                <!-- START: section-phase2-donor-tcell-activation -->
                <section id="section-phase2-donor-tcell-activation" class="content-section" aria-labelledby="section-heading-phase2-donor-tcell-activation">
                    <h2 id="section-heading-phase2-donor-tcell-activation" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">II. Donor T-cell activation.</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>The inflammatory cytokines stimulate antigen presenting cells (APC); followed by activation and proliferation of the donor lymphocytes.</li>
                            <li>The APC present host antigens not recognized by the donor lymphocytes.</li>
                            <li>The lymphocytes then multiply and differentiate under the influence of IL-2.</li>
                        </ul>
                        <figure>
                            <img src="../assets/images/2025_06_15_2bf39b8f0cf607742d85g-12-1.jpg" alt="Diagram illustrating Phase II of GVHD: Donor T-cell activation. Host APCs, stimulated by inflammatory cytokines, present host alloantigens to donor T-cells. This, along with co-stimulation and IL-2, leads to donor T-cell proliferation and differentiation." class="content-image">
                            <figcaption>ACTIVATION AND PROLIFERATION OF DONOR LYMPHOCYTES</figcaption>
                        </figure>
                    </div>
                </section>
                <!-- END: section-phase2-donor-tcell-activation -->

                <!-- START: section-phase3-attack-target-tissues -->
                <section id="section-phase3-attack-target-tissues" class="content-section" aria-labelledby="section-heading-phase3-attack-target-tissues">
                    <h2 id="section-heading-phase3-attack-target-tissues" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">III. Attack of Target Tissues.</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>GVHD is primarily mediated by cytoxic T lymphocytes (CD8+) but helper T lymphocytes (CD4+) and NK cells are also involved.</li>
                            <li>The host cells are destroyed by either direct cytotoxic activity or inflammatory cytokines.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-phase3-attack-target-tissues -->

                <!-- START: section-decreasing-damage-host -->
                <section id="section-decreasing-damage-host" class="content-section" aria-labelledby="section-heading-decreasing-damage-host">
                    <h2 id="section-heading-decreasing-damage-host" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Decreasing the damage to the host.</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>This can be divided into giving less rigorous conditioning regimens or blocking the cytokines or other products that lead to the activation of APC's.</li>
                            <li>Antibiotics have been shown to decrease the frequency of acute GVHD.</li>
                            <li>TNF-alpha inhibitors have been tried to decrease GVHD</li>
                            <li>Other investigations have shown delay in the development of acute GVHD but not reduction rate with the use of prophylactic TNF-alpha inhibitors.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-decreasing-damage-host -->

                <!-- START: section-stopping-activation-donor-lymphocytes -->
                <section id="section-stopping-activation-donor-lymphocytes" class="content-section" aria-labelledby="section-heading-stopping-activation-donor-lymphocytes">
                    <h2 id="section-heading-stopping-activation-donor-lymphocytes" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Stopping activation and proliferation of donor lymphocytes.</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Cyclosporine</li>
                            <li>Methotrexate</li>
                            <li>Tacrolimus</li>
                            <li>Sirolimus</li>
                            <li>Mycophenolate mofetil</li>
                            <li>Steroids</li>
                            <li>Alemtuzamab (Campath)</li>
                            <li>Anti-IL2 antibodies</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-stopping-activation-donor-lymphocytes -->

                <!-- START: section-methotrexate -->
                <section id="section-methotrexate" class="content-section" aria-labelledby="section-heading-methotrexate">
                    <h2 id="section-heading-methotrexate" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Methotrexate.</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Methotrexate is a folate antimetabolite</li>
                            <li>As a single agent significant GVHD develops in 70%</li>
                            <li>It has found a significant role in prevention when used in combination with other immune suppressant medications.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-methotrexate -->

                <!-- START: section-cyclosporine -->
                <section id="section-cyclosporine" class="content-section" aria-labelledby="section-heading-cyclosporine">
                    <h2 id="section-heading-cyclosporine" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Cyclosporine.</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Cyclosporine is a calcineurin inhibitor</li>
                            <li>Inhibition of calcineurin prevents the transcription of TNF-alpha and many cytokines (IL-2, IL-3, IL-4) which decreases the proliferation of lymphocytes.</li>
                            <li>Notwithstanding, a 40% development rate for acute GVHD (Grade II-IV) in HLA-matched transplants has been reported.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-cyclosporine -->

                <!-- START: section-summary-gvhd -->
                <section id="section-summary-gvhd" class="content-section" aria-labelledby="section-heading-summary-gvhd">
                    <h2 id="section-heading-summary-gvhd" class="section-heading">
                         <span class="heading-icon"></span>
                        <span class="heading-text">Summary.</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Graft vs. Host disease is a syndrome that occurs when immune cells from a donor attack the host's normal cells.</li>
                            <li>GVHD is divided into acute and chronic depending on whether the initial symptoms developed before 100 days following Bone Marrow Transplant (BMT).</li>
                            <li>3 phases to the development of acute GVHD: Damage to host tissues; activation and proliferation of donor lymphocytes; attack on the host cells.</li>
                        </ul>
                    </div>
                </section>
                <!-- END: section-summary-gvhd -->

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="immunology-25b-transplantation-immunology-details.html" class="nav-button"> 
                        <span class="nav-icon"></span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 100%;"></div> 
                        </div>
                       <span class="progress-text">Lecture 39 of 39</span> 
                    </div>
                    <a href="#" class="nav-button disabled"> <!-- Last chunk -->
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon"></span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script> 
</body>
</html>